GC
MRSN

Grimes & Company’s Mersana Therapeutics MRSN Stock Holding History

Grimes & Company’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-563
Closed -$4.84K – 422
2025
Q1 		$4.84K Sell
563
-37
-6% -$571 ﹤0.01% 368
2024
Q4 		$21.4K Hold
600
– – ﹤0.01% 380
2024
Q3 		$28.3K Hold
600
– – ﹤0.01% 362
2024
Q2 		$30.1K Sell
600
-14
-2% -$1.01K ﹤0.01% 344
2024
Q1 		$68.8K Sell
614
-12
-2% -$1.19K ﹤0.01% 334
2023
Q4 		$36.3K Sell
626
-19
-3% -$764 ﹤0.01% 324
2023
Q3 		$20.5K Buy
645
+15
+2% +$713 ﹤0.01% 300
2023
Q2 		$51.8K Buy
630
+6
+1% +$878 ﹤0.01% 301
2023
Q1 		$64.1K Buy
624
+13
+2% +$1.82K ﹤0.01% 290
2022
Q4 		$89.5K Buy
611
+4
+0.7% +$676 ﹤0.01% 279
2022
Q3 		$103K Buy
607
+10
+2% +$1.63K 0.01% 264
2022
Q2 		$69K Buy
597
+22
+4% +$2.07K ﹤0.01% 268
2022
Q1 		$57K Buy
+575
New +$67.2K ﹤0.01% 296

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $12.3B AUM 37.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return